Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM)
- PMID: 31100014
- DOI: 10.1200/CCI.18.00128
Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM)
Abstract
Purpose: Patient-reported outcome measures (PROMs) for symptom monitoring during cancer therapy have been shown to have a positive impact on outcomes. These findings have primarily been shown for patients receiving intravenous chemotherapy. In addition, there is known discordance between physician reporting of symptoms and patient self-report. This initiative sought to describe patient-reported symptom burden and medication adherence and to indicate the degree of PROM results being discussed with the provider as indicated by documentation in the medical record for patients taking oral oncolytic therapy.
Methods: The Michigan Oncology Quality Consortium (MOQC) PROM, which included symptom ratings, medication adherence, and patient confidence in self-management, was completed during outpatient visits and compared with corresponding data documented in the electronic medical record (EMR).
Results: There were 82 completed PROMs. Approximately half included at least one symptom rated as severe (46%). Sixty-five percent of reported severe symptoms were documented in the EMR. Patient-reported moderate-to-severe pain was most likely to be documented in the EMR (100%), whereas patient-reported moderate-to-severe depression and anxiety were least likely to be documented (21%). Of the total symptoms documented, grading of symptom severity matched that of the patients' own report for 11% of severe symptoms. Adherence to oral oncolytics was excellent for 63% of patients, and patient adherence was documented in 7% of provider notes.
Conclusion: Patients frequently reported moderate-to-severe symptoms, and approximately 40% of patients reported nonadherence. Clinician report (documented in the EMR) of the patient symptom burden, symptom severity, and adherence to oral oncolytic therapy was not consistent with the patients' self-report. Use of a PROM for patients taking oral oncolytics has the opportunity to improve symptom management and medication adherence.
Similar articles
-
Improving Oral Oncolytic Patient Self-Management.J Oncol Pract. 2016 Sep;12(9):e864-9. doi: 10.1200/JOP.2016.011304. Epub 2016 Aug 16. J Oncol Pract. 2016. PMID: 27531381
-
The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices.Support Care Cancer. 2017 Jun;25(6):1797-1807. doi: 10.1007/s00520-017-3584-0. Epub 2017 Jan 20. Support Care Cancer. 2017. PMID: 28108821
-
Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy.J Oncol Pract. 2017 Apr;13(4):e395-e400. doi: 10.1200/JOP.2016.018390. Epub 2017 Feb 14. J Oncol Pract. 2017. PMID: 28195813
-
A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data.J Manag Care Spec Pharm. 2019 Oct;25(10):1125-1132. doi: 10.18553/jmcp.2019.25.10.1125. J Manag Care Spec Pharm. 2019. PMID: 31556821 Free PMC article.
-
Implementing Patient-Reported Outcome Measures in Clinical Breast Cancer Care: A Systematic Review.Value Health. 2019 Oct;22(10):1197-1226. doi: 10.1016/j.jval.2019.04.1927. Epub 2019 Aug 29. Value Health. 2019. PMID: 31563263
Cited by
-
When can cancer patient treatment nonadherence be considered intentional or unintentional? A scoping review.PLoS One. 2023 May 3;18(5):e0282180. doi: 10.1371/journal.pone.0282180. eCollection 2023. PLoS One. 2023. PMID: 37134109 Free PMC article.
-
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program.Cancers (Basel). 2022 Jan 28;14(3):660. doi: 10.3390/cancers14030660. Cancers (Basel). 2022. PMID: 35158928 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources